These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

622 related articles for article (PubMed ID: 27528374)

  • 1. Safety and Efficacy of Incretin-Based Therapies in Patients With Type 2 Diabetes Mellitus and CKD: A Systematic Review and Meta-analysis.
    Howse PM; Chibrikova LN; Twells LK; Barrett BJ; Gamble JM
    Am J Kidney Dis; 2016 Nov; 68(5):733-742. PubMed ID: 27528374
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differentiating among incretin therapies: a multiple-target approach to type 2 diabetes.
    Cornell S
    J Clin Pharm Ther; 2012 Oct; 37(5):510-24. PubMed ID: 22436069
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clarifying the role of incretin-based therapies in the treatment of type 2 diabetes mellitus.
    Campbell RK
    Clin Ther; 2011 May; 33(5):511-27. PubMed ID: 21665040
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Incretin-based agents in type 2 diabetic patients at cardiovascular risk: compare the effect of GLP-1 agonists and DPP-4 inhibitors on cardiovascular and pancreatic outcomes.
    Zhang Z; Chen X; Lu P; Zhang J; Xu Y; He W; Li M; Zhang S; Jia J; Shao S; Xie J; Yang Y; Yu X
    Cardiovasc Diabetol; 2017 Mar; 16(1):31. PubMed ID: 28249585
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Incretin treatment and risk of pancreatitis in patients with type 2 diabetes mellitus: systematic review and meta-analysis of randomised and non-randomised studies.
    Li L; Shen J; Bala MM; Busse JW; Ebrahim S; Vandvik PO; Rios LP; Malaga G; Wong E; Sohani Z; Guyatt GH; Sun X
    BMJ; 2014 Apr; 348():g2366. PubMed ID: 24736555
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of efficacy and safety of three novel hypoglycemic agents in patients with severe diabetic kidney disease: A systematic review and network meta-analysis of randomized controlled trials.
    Li Y; Hu Y; Huyan X; Chen K; Li B; Gu W; Mu Y
    Front Endocrinol (Lausanne); 2022; 13():1003263. PubMed ID: 36353233
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis.
    Amori RE; Lau J; Pittas AG
    JAMA; 2007 Jul; 298(2):194-206. PubMed ID: 17622601
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effects of incretin-based therapies on β-cell function and insulin resistance in type 2 diabetes: A systematic review and network meta-analysis combining 360 trials.
    Wu S; Gao L; Cipriani A; Huang Y; Yang Z; Yang J; Yu S; Zhang Y; Chai S; Zhang Z; Sun F; Zhan S
    Diabetes Obes Metab; 2019 Apr; 21(4):975-983. PubMed ID: 30536884
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Incretin-based therapies and risk of pancreatic cancer in patients with type 2 diabetes: A meta-analysis of randomized controlled trials.
    Wang H; Liu Y; Tian Q; Yang J; Lu R; Zhan S; Haukka J; Hong T
    Diabetes Obes Metab; 2018 Apr; 20(4):910-920. PubMed ID: 29193572
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Incretin based treatments and mortality in patients with type 2 diabetes: systematic review and meta-analysis.
    Liu J; Li L; Deng K; Xu C; Busse JW; Vandvik PO; Li S; Guyatt GH; Sun X
    BMJ; 2017 Jun; 357():j2499. PubMed ID: 28596247
    [No Abstract]   [Full Text] [Related]  

  • 11. Pharmacokinetics and clinical use of incretin-based therapies in patients with chronic kidney disease and type 2 diabetes.
    Scheen AJ
    Clin Pharmacokinet; 2015 Jan; 54(1):1-21. PubMed ID: 25331711
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of drugs for people with type 2 diabetes mellitus and chronic kidney disease on kidney and cardiovascular outcomes: A systematic review and network meta-analysis of randomized controlled trials.
    Yang Q; Lang Y; Yang W; Yang F; Yang J; Wu Y; Xiao X; Qin C; Zou Y; Zhao Y; Kang D; Liu F
    Diabetes Res Clin Pract; 2023 Apr; 198():110592. PubMed ID: 36842477
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of GLP-1 receptor agonists and DPP-4 inhibitors: meta-analysis and systematic review.
    Aroda VR; Henry RR; Han J; Huang W; DeYoung MB; Darsow T; Hoogwerf BJ
    Clin Ther; 2012 Jun; 34(6):1247-1258.e22. PubMed ID: 22608780
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Review of glucagon-like peptide-1 receptor agonists for the treatment of type 2 diabetes mellitus in patients with chronic kidney disease and their renal effects.
    Sloan LA
    J Diabetes; 2019 Dec; 11(12):938-948. PubMed ID: 31318152
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cardiovascular and renal outcomes with SGLT-2 inhibitors versus GLP-1 receptor agonists in patients with type 2 diabetes mellitus and chronic kidney disease: a systematic review and network meta-analysis.
    Yamada T; Wakabayashi M; Bhalla A; Chopra N; Miyashita H; Mikami T; Ueyama H; Fujisaki T; Saigusa Y; Yamaji T; Azushima K; Urate S; Suzuki T; Abe E; Wakui H; Tamura K
    Cardiovasc Diabetol; 2021 Jan; 20(1):14. PubMed ID: 33413348
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dipeptidyl Peptidase-4 Inhibitors in Chronic Kidney Disease: A Systematic Review of Randomized Clinical Trials.
    Walker SR; Komenda P; Khojah S; Al-Tuwaijri W; MacDonald K; Hiebert B; Tangri N; Nadurak SWD; Ferguson TW; Rigatto C; Tangri N
    Nephron; 2017; 136(2):85-94. PubMed ID: 28178698
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Incretin-based therapy in type 2 diabetes: An evidence based systematic review and meta-analysis.
    Waldrop G; Zhong J; Peters M; Goud A; Chen YH; Davis SN; Mukherjee B; Rajagopalan S
    J Diabetes Complications; 2018 Jan; 32(1):113-122. PubMed ID: 29074120
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The cardiovascular effect of incretin-based therapies among type 2 diabetes: a systematic review and network meta-analysis.
    Wu S; Cipriani A; Yang Z; Yang J; Cai T; Xu Y; Quan X; Zhang Y; Chai S; Sun F; Zhan S
    Expert Opin Drug Saf; 2018 Mar; 17(3):243-249. PubMed ID: 29320889
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of SGLT2 inhibitors on cardiovascular, renal and safety outcomes in patients with type 2 diabetes mellitus and chronic kidney disease: A systematic review and meta-analysis.
    Toyama T; Neuen BL; Jun M; Ohkuma T; Neal B; Jardine MJ; Heerspink HL; Wong MG; Ninomiya T; Wada T; Perkovic V
    Diabetes Obes Metab; 2019 May; 21(5):1237-1250. PubMed ID: 30697905
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Incretin therapies in the management of patients with type 2 diabetes mellitus and renal impairment.
    Dejager S; Schweizer A
    Hosp Pract (1995); 2012 Apr; 40(2):7-21. PubMed ID: 22615074
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.